These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 23886182)

  • 1. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
    Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
    Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
    Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
    Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
    Ma JG; Wang NJ; Yu WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
    Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
    Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
    Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
    Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and survival analysis of very young (age<35) breast cancer patients.
    Wei XQ; Li X; Xin XJ; Tong ZS; Zhang S
    Asian Pac J Cancer Prev; 2013; 14(10):5949-52. PubMed ID: 24289606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
    Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of non-metastatic male breast cancer: 118 patients.
    Arslan UY; Oksüzoğlu B; Ozdemir N; Aksoy S; Alkış N; Gök A; Kaplan MA; Gümüş M; Berk V; Uncu D; Baykara M; Colak D; Uyetürk U; Türker I; Işıkdoğan A
    Med Oncol; 2012 Jun; 29(2):554-60. PubMed ID: 21573973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel prognostic markers for patients with triple-negative breast cancer.
    Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
    Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
    Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.